The FDA’s May 16, 2025, clearance of Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio—the first blood test aiding Alzheimer’s diagnosis—revolutionizes access for 7 million U.S. sufferers, measuring amyloid plaques via simple draws for 55+ symptomatic adults, slashing PET/lumbar costs from $4,637 to $500 while curbing radiation. Quanterix/Fujirebio’s ratio—high pTau217/low β-amyloid signals pathology—boasts 90%+ accuracy in early stages, per Johns Hopkins validations, enabling 91% pre-symptomatic interest for timely lecanemab/donanemab interventions.
Roche’s October 13 Elecsys pTau181—primary care’s rule-out tool—achieves 97.9% NPV in low-prevalence cohorts, per multicenter trials of 312, empowering GPs to triage 4-in-5 undiagnosed via 2022 AUR guidelines. Not standalone—amyloid range flags 90%+ likelihoods—yet complements PET/spinals, accelerating NIH’s $3.8 billion research to 13 million projections by 2050. Hampel’s Mol Psychiatry benchmarks 5481-5503 proteins for 2021’s 90% sensitivity, reaffirmed 2025.
Ethical frontiers: overdiagnosis risks (thyroid echoes) demand clinical judgment; yet, UCL’s 2025 Lancet ties to 20% MACE drops via early therapies. As Quanterix’s HD-X automates, insurance coverage—post-breakthrough status—halves 2.2 billion global impairments by 2050. Lumipulse’s dawn—$500 accessibility—illuminates Alzheimer’s shadows.
